Evidence map›Paper›PMID 39551717›Full record

ArticleBritish journal of haematology2025

Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.

Aditi Vedi, Sarah Maria Leiter, Irum Latif Memon, Arunthethy Mahendrayogam, Elsje Van Rijswijk, Urmila Uparkar, Geoff Shenton, Amelie Trinquand, Katherine Clesham, Vanessa McLelland and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Aditi VediCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID https://orcid.org/0000-0001-6761-6510
Sarah Maria LeiterCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID https://orcid.org/0000-0001-8321-3260
Irum Latif MemonGreat Ormond Street Hospital, London, UK.
Arunthethy MahendrayogamCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Elsje Van RijswijkRoyal Marsden Hospital, Surrey, UK.
Urmila UparkarRoyal Marsden Hospital, Surrey, UK.
Geoff ShentonNewcastle Hospitals NHS Foundation Trust, Newcastle, UK.
Amelie TrinquandNational Children's Cancer Service, Children's Health Ireland at Crumlin, Dublin, Ireland.ORCID https://orcid.org/0009-0004-4598-9358
Katherine CleshamUniversity College London Hospital, London, UK.
Vanessa McLellandUniversity Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Helen CampbellManchester University Hospitals, Manchester, UK.
Katharine PatrickSheffield Children's NHS Foundation Trust, Sheffield, UK.
Lyndsey ThompsonRoyal Belfast Hospital for Sick Children, Belfast, UK.
Susan BairdRoyal Hospital for Children and Young People, Edinburgh, UK.
Philip ConnorHealth Care Research Wales, Cardiff, UK.
Donna LancasterRoyal Marsden Hospital, Surrey, UK.
Beki JamesLeeds Children's Hospital, Leeds, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukaemia (APL), defined by the t(15;17)(q24;q21) translocation, accounts for 5%-10% of paediatric acute myeloid leukaemia cases. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are key treatments, though ATO access varies. We evaluated treatment, complications and survival in 50 UK paediatric APL patients diagnosed between 2014 and 2021. All patients received ATRA and most received ATO. Event-free survival was lower in high-risk patients (85% vs. 100%, p = 0.03), and those not receiving ATO at diagnosis. All relapsed patients could be salvaged with ATO. Addressing ATO availability and consistent funding is crucial to ensure timely treatment and improve outcomes.

Indexed as

Arsenic TrioxideLeukemia, Promyelocytic, AcuteAdolescentAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolFemaleHumansInfantIrelandMaleTretinoinUnited KingdomArsenic TrioxideTretinoinall‐trans retinoic acidAPLarsenic trioxideLeukaemiaPaediatric

Identifiers

PMID39551717
PMCPMC11739768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.